February 2024 updates to the website

The website has now been updated following February's LSCMMG

The following guidelines have been added/updated:

Denosumab 120mg shared care - added

Denosumab 60mg shared care - updated

Atrial fibrillation guideline - update to follow pending amendments

Rimegepant position statement - added

Testosterone shared care - updated

Dosulepin guidance for primary care - added

Tirzepatide for type 2 diabetes position statement - to follow pending LSC ICB executive committee

Tirzepatide for weight loss position statement - to follow pending LSC ICB executive committee

The following medicines have been added/updated following the latest Clinical Effectiveness Group (CEG) / Commissioning Resource Group (CRG) meeting:

Morphine Sulfate Orodispersible Tablets (Actimorph®) - severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

Anastrozole - Primary prevention of breast cancer in postmenopausal women at moderate or high risk

Ulipristal (Esmya) - for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed (RAG review)

Ibandronic acid injection - Treatment of post menopausal osteoporosis (RAG review)

Denosumab 120mg - Bone metastasis from solid tumours NICE TA265 (RAG review)

Empagliflozin - chronic heart failure with preserved or mildly reduced ejection fraction NICE TA929

Empagliflozin - chronic kidney disease NICE TA942

The following Items will be updated and added to the website following the next  Clinical Effectiveness Group (CEG) / Commissioning Resource Group (CRG) Meeting:

Hybrid closed-loop interim position statement - to follow pending amendments and ratification

Melatonin liquid (Ceyesto)